Sergio Quezada

Net worth: 466 571 $ as of 2024-03-30

49 year

Consumer Services

Health Technology

Profile

Sergio Quezada is the founder of Achilles Therapeutics UK Ltd.
(founded in 2016) and Achilles Therapeutics Plc (founded in 2020), where he holds the title of Chief Scientific Officer.
He is currently a Professor-Cancer Institute at University College London since 2011.
Dr. Quezada obtained his undergraduate degree from Pontificia Universidad Católica de Chile and his doctorate from Dartmouth Medical School.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
ACHILLES THERAPEUTICS PLC 0.92%	2023-01-31	373,257 ( 0.92% )	466 571 $	2024-03-30

Sergio Quezada active positions

Companies	Position	Start
ACHILLES THERAPEUTICS PLC	Founder	2020-10-31
University College London	Corporate Officer/Principal	2010-12-31

All active positions of Sergio Quezada

Former positions of Sergio Quezada

Companies	Position	End
Achilles Therapeutics UK Ltd. Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom.	Founder	-